These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 35295921)

  • 1. Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma.
    Serzan MT; Atkins MB
    J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 35295921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
    Atkins MB; Tannir NM
    Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
    Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
    Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
    [No Abstract]   [Full Text] [Related]  

  • 5. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma.
    Tegos T; Tegos K; Dimitriadou A; Dimitriadis G
    J BUON; 2019; 24(4):1340-1353. PubMed ID: 31646776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
    Zhuang TZ; Case K; Olsen TA; Brown JT; Carthon BC; Kucuk O; Goldman J; Harris W; Bilen MA; Nazha B
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
    Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to first-line treatment of advanced renal cell carcinoma.
    George DJ; Lee CH; Heng D
    Ther Adv Med Oncol; 2021; 13():17588359211034708. PubMed ID: 34527080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.
    Krawczyk K; Śladowska K; Holko P; Kawalec P
    Front Pharmacol; 2023; 14():1223929. PubMed ID: 37745049
    [No Abstract]   [Full Text] [Related]  

  • 12. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
    Vano YA; Ladoire S; Elaidi R; Dermeche S; Eymard JC; Falkowski S; Gross-Goupil M; Malouf G; Narciso B; Sajous C; Tartas S; Voog E; Ravaud A
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in personalized therapy for metastatic renal cell carcinoma.
    Fujiwara R; Kageyama S; Yuasa T
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):647-655. PubMed ID: 35531636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma.
    Ivanyi P; Wiegmann JP; Eggers H; Grünwald V
    Adv Ther; 2023 Sep; 40(9):3610-3619. PubMed ID: 37434067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
    Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
    Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on immunotherapy for renal cancer.
    Canales Rojas R
    Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
    Chau V; Bilusic M
    Cancer Manag Res; 2020; 12():7321-7330. PubMed ID: 32884346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
    Li S; Li J; Peng L; Li Y; Wan X
    Front Pharmacol; 2021; 12():718014. PubMed ID: 34566643
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.